Tadakazu Hisamatsu

机构：Kyorin University · ORCID：0000-0002-1178-3536

发表论文 645 篇 · 总被引 14995 次 · h-index 60

代表论文

• Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials (2025 · The Lancet · 被引 52)
• Vaginal Lactobacillus crispatus in early pregnancy associates with favorable gestational outcomes in a Japanese maternal-neonatal microbiome cohort (2025 · Nature Communications · 被引 10)
• Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial (2026 · ˜The œLancet. Gastroenterology & hepatology · 被引 8)
• Expert consensus on diagnostic guidelines for pediatric inflammatory bowel disease in Japan (2025 · Journal of Gastroenterology · 被引 4)
• Guselkumab in East Asians With Moderate‐to‐Severe Ulcerative Colitis: Subgroup Analysis of the QUASAR Induction and Maintenance Studies (2025 · Journal of Gastroenterology and Hepatology · 被引 4)
• Five-year efficacy and safety of guselkumab for moderately to severely active Crohn’s disease: Results from the phase 2 GALAXI 1 trial (2026 · Inflammatory Bowel Diseases · 被引 3)